FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report

This article was originally published in The Pink Sheet Daily

01 Oct 2014
News

Sarah Karlin pinkeditor@informa.com

Executive Summary

Industry comments lead to subtle but notable changes; agency also makes a few deletions, additions of its own including deemphasizing cost-control projects, highlighting antibiotic development and changing the status of its facility improvements.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

BioPharmaceutical Consumer Medical Device

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS076495

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS076495

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

FDA Gives Innovation, Harmonization Added Attention In Final Priorities Report

News

Executive Summary

Related Content

FDA Budget Issues Creep Into Strategic Priorities

Topics

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert